American Century Companies
AXDX

American Century Companies’s Accelerate Diagnostics AXDX Stock Holding History

American Century Companies’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,265
Closed -$421K – 1504
2019
Q3 		$421K Buy
+2,265
New +$438K ﹤0.01% 1113

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

American Century Companies's AXDX Position: Q4 2019 in Review

American Century Companies sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 2,265 shares — an estimated $421K sold.

American Century Companies first reported a position in AXDX in Q3 2019 and held it in 1 quarter. The position peaked at $421K in Q3 2019. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

  • American Century Companies reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
  • American Century Companies sold 2,265 Accelerate Diagnostics shares in Q4 2019, an estimated $421K.
  • American Century Companies first reported a position in Accelerate Diagnostics in Q3 2019 and held it in 1 quarter.
  • American Century Companies's Accelerate Diagnostics position peaked at $421K in Q3 2019.
  • 109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on American Century Companies's 13F filing for Q4 2019, filed 12 Feb 2020.